Can I Take Folate with Metformin?

The Short Answer: Folate Is Safe with Metformin

Folate does not interfere with metformin's glucose-lowering effect, and there is no established pharmacokinetic pathway by which metformin reduces serum folate. The two can be taken at the same time without a separation window. Metformin's current FDA prescribing information does address a related nutrient, noting that use of the drug may lower vitamin B12 levels through interference with absorption (metformin label, accessdata.fda.gov, verify current section and wording before citing verbatim). That B12 effect, not a folate effect, is why folate and B12 status come up together in metformin care.

Why Clinicians Still Bring Up Folate

Metformin is thought to reduce vitamin B12 absorption in the terminal ileum by interfering with calcium-dependent uptake of the B12-intrinsic factor complex. Cohort studies of long-term metformin users have found meaningfully higher rates of subnormal B12 compared with non-users; one frequently cited analysis reported roughly 30 percent of long-term metformin users with subnormal B12 after over a decade of treatment (PubMed). The exact sample size, follow-up duration, and percentage in that study should be re-verified against the abstract before publication, since precise figures like these are easy to misstate secondhand.

B12 is required to convert homocysteine back to methionine using 5-methyltetrahydrofolate (5-MTHF) as the methyl donor. When B12 is low, that reaction slows. Folate can accumulate in its methylated, "trapped" form and becomes less available for DNA synthesis. This is the methyl-trap hypothesis, described in older biochemistry literature (PubMed).

Folate Depletion Is Not the Primary Concern

Serum folate itself is rarely reduced by metformin. A cross-sectional analysis of type 2 diabetes patients found no significant difference in serum folate between metformin users and non-users, while B12 differences were significant (PubMed). The practical clinical priority for metformin users is B12 status, not folate status, even though the two nutrients are metabolically linked.

How Metformin Affects the Folate Cycle

The One-Carbon Metabolism Pathway

Folate and B12 share a metabolic pathway called one-carbon metabolism. Dietary folate is reduced stepwise to 5-methyltetrahydrofolate (5-MTHF), which donates a methyl group to homocysteine to form methionine. That reaction is catalyzed by methionine synthase, which requires B12 as a cofactor. Without adequate B12, 5-MTHF cannot be used and accumulates instead of cycling back into active folate metabolism, which can reduce the folate available for DNA synthesis.

The NIH Office of Dietary Supplements describes this coupled relationship: B12 deficiency can make folate functionally unavailable by trapping it in the 5-methylTHF form (NIH ODS Folate fact sheet).

Homocysteine as a Practical Marker

Elevated homocysteine is a usable, if imperfect, signal of disrupted one-carbon metabolism. A meta-analysis of randomized trials found metformin use associated with a modest average increase in homocysteine compared with controls (PubMed; the exact number of trials, participants, and mean difference reported in that analysis should be confirmed before quoting a specific figure). Elevated homocysteine has been associated with increased cardiovascular risk in observational data, though homocysteine-lowering supplementation has not consistently been shown to reduce cardiovascular events in trials (American Heart Association, Circulation). Both folate and B12 supplementation can lower homocysteine, but in metformin users, correcting B12 addresses the more likely root cause.

A Preliminary, Unconfirmed Mechanism

A small study has proposed that metformin's activation of AMPK could also affect folate transporter expression in intestinal cells, which would suggest a direct effect on folate uptake independent of B12 status (PubMed). This idea has not been confirmed in larger human studies and should be treated as a research hypothesis, not an established mechanism, until more evidence accumulates.

MTHFR Variants: When Folate Form Matters More

The MTHFR gene encodes the enzyme that converts folate into its active 5-MTHF form. Two common variants, C677T and A1298C, reduce that enzyme's activity.

MTHFR C677T Homozygosity

People homozygous for C677T (the TT genotype) have substantially reduced MTHFR enzyme activity compared with those without the variant, and this genotype is common in some populations (population genetics literature, PubMed; the specific activity-reduction percentage and prevalence figures in this source should be verified before republishing as exact numbers). In people with reduced MTHFR activity, standard folic acid supplementation produces less active 5-MTHF, and homocysteine can run higher at baseline. Adding metformin's effect on B12 on top of that can compound the risk of elevated homocysteine.

Methylfolate vs. Folic Acid

5-methyltetrahydrofolate (sold as Metafolin, Deplin, and generic "methylfolate" products) is already in the bioactive form and does not require MTHFR enzyme activity to become usable. A randomized trial comparing 5-MTHF and folic acid found the two forms raised red-cell folate similarly in people without MTHFR variants, with 5-MTHF performing better in people with the TT genotype (PubMed). For metformin users who know they carry MTHFR variants, methylfolate is a reasonable preferred form to discuss with a clinician.

Should Everyone on Metformin Get MTHFR Testing?

Routine MTHFR testing is not recommended for the general population by clinical genetics bodies, largely because the variant's clinical significance for most common conditions is not well established (PubMed). If a patient on metformin has persistently elevated homocysteine despite adequate B12 and folate intake, genotyping is a reasonable next step for a clinician to consider rather than a first-line test.

Evidence-Status Assessment: Metformin and Folate

This table separates what current evidence actually supports from what is plausible but unconfirmed, so a clinician or pharmacist reviewing this page can see where the load-bearing claims sit.

A pharmacist or clinician reviewing a specific patient should confirm: current B12 and folate status, any MTHFR testing on file, concurrent use of other folate-antagonist drugs, and pregnancy status or planning, before making a supplementation recommendation.

Pregnancy, Neural Tube Defects, and Metformin

Metformin is sometimes continued in pregnancy for gestational diabetes or polycystic ovary syndrome (PCOS). Folate status matters in this context regardless of metformin use.

Neural Tube Defect Prevention

The U.S. Preventive Services Task Force recommends that people who are planning or capable of pregnancy take a daily supplement containing 400 to 800 mcg of folic acid, with a higher dose recommended for those with a prior pregnancy affected by a neural tube defect (USPSTF recommendation). Because metformin does not appear to deplete serum folate directly, the standard neural-tube-defect-prevention dose remains appropriate for metformin users; a clinician should confirm the exact recommended dose for anyone with a prior affected pregnancy. The main additional consideration for metformin users is making sure B12 is also adequate, since B12 deficiency can independently affect fetal outcomes and can be mistaken for or coexist with folate insufficiency.

PCOS Patients on Metformin

Women with PCOS prescribed metformin for insulin sensitization face two overlapping considerations: metformin's long-term effect on B12, and the folate needs of a potential pregnancy. A study comparing PCOS patients on and off metformin reported lower B12 concentrations in the metformin group, with no significant difference in folate (PubMed; the specific B12 values reported should be verified before being quoted as exact figures). This is consistent with the broader pattern: B12 supplementation, alongside standard folate intake, is the relevant intervention for this group.

Dosing: How Much Folate Is Right for Metformin Users?

There is no metformin-specific folate dose in current guidelines, because metformin does not directly deplete folate. Dosing follows standard clinical context, and any change to a personal dose should go through a clinician.

Standard Adult Intake

The Recommended Dietary Allowance for folate in non-pregnant adults is 400 mcg of dietary folate equivalents per day, per the NIH Office of Dietary Supplements (NIH ODS folate fact sheet). Most multivitamins contain 400 to 800 mcg. The tolerable upper intake level from supplemental folic acid is 1,000 mcg/day for adults, based on the concern that high folic acid intake can mask the blood-count signs of B12 deficiency while the underlying neurological damage from B12 deficiency continues. That risk is not eliminated by taking metformin.

Folate for Elevated Homocysteine

When homocysteine is elevated, some clinicians consider higher-dose folic acid or 5-MTHF alongside B12 supplementation. A Cochrane-associated review found that folic acid supplementation reliably lowers homocysteine across populations, with the magnitude depending on baseline folate and B12 status (PubMed; trial count and exact percentage reduction should be confirmed against the source before citing precisely). Any specific dose for homocysteine reduction should come from a treating clinician rather than self-directed supplementation, since the clinical benefit of homocysteine-lowering itself is not firmly established.

No Dose Separation Needed

Folate is absorbed through the proton-coupled folate transporter (PCFT/SLC46A1) and the reduced folate carrier (RFC/SLC19A1) in the small intestine. Metformin is absorbed largely through organic cation transporters (OCT1, OCT3). These pathways do not compete, so there is no pharmacologic reason to separate the timing of the two.

Monitoring Recommendations for Metformin Users

The American Diabetes Association's Standards of Care addresses this directly: long-term metformin use is associated with vitamin B12 deficiency, and periodic B12 measurement should be considered in metformin-treated patients (ADA Standards of Medical Care in Diabetes 2024).

A Practical Baseline Panel

A reasonable monitoring approach for patients starting or continuing metformin, to review with a clinician:

• Serum B12 at baseline, then periodically during long-term use, particularly at higher doses or after several years of treatment
• Serum folate at baseline if dietary intake is a concern or pregnancy is planned
• Homocysteine if B12 is low-normal or cardiovascular risk is a specific concern
• Complete blood count to screen for macrocytic anemia, which can signal either B12 or folate insufficiency

A systematic review of metformin users found B12 deficiency and borderline deficiency together affecting a substantial minority of long-term users (PubMed; exact deficiency and borderline-deficiency percentages from this review should be verified before being cited as precise figures).

Methylmalonic Acid as a Functional B12 Marker

Serum B12 can appear normal while functional B12 deficiency is still present. Methylmalonic acid (MMA) is a more sensitive marker of intracellular B12 sufficiency and has been used as a reference standard in B12 research (PubMed). For metformin patients with neurological symptoms or borderline B12 levels, an MMA level, ordered by a clinician, can add diagnostic clarity.

Drug Interactions Beyond Folate: Anticonvulsants and Metformin

Some patients take both metformin and enzyme-inducing anticonvulsants such as phenytoin or carbamazepine. Unlike metformin, these drugs are established folate antagonists: they can lower serum folate through hepatic enzyme induction that accelerates folate breakdown (PubMed; the specific percentage reduction reported in this source should be confirmed rather than quoted from memory). Patients on metformin plus an enzyme-inducing anticonvulsant face two separate mechanisms working on the same nutrient system: B12 depletion from metformin and direct folate depletion from the anticonvulsant. This combination genuinely warrants a clinician-directed folate plan alongside B12 monitoring.

Trimethoprim and methotrexate are separate folate-pathway antagonists sometimes used alongside metformin in complex patients; both inhibit dihydrofolate reductase. For patients on either of these plus metformin, a treating clinician should explicitly assess folate status.

Special Populations

Older Adults

Adults over 65 tend to absorb B12 less efficiently due to age-related changes in stomach acid and intrinsic factor production, independent of metformin. Adding metformin to an already reduced absorption baseline can raise deficiency risk further. Older-adult B12 deficiency has been documented in general population studies even without metformin use (PubMed; the specific prevalence figure in this source should be checked before citing it precisely). Separately, some research suggests that folic acid intake well above the 1,000 mcg/day upper limit may worsen cognitive outcomes specifically when B12 is deficient (PubMed), which is a reason to confirm B12 status before taking high-dose folic acid, particularly in older adults.

Bariatric Surgery Patients

Patients who have had Roux-en-Y gastric bypass and are also prescribed metformin, for residual type 2 diabetes or PCOS, face impaired absorption of both B12 and folate from the surgery itself. Standard post-bariatric micronutrient protocols already include folic acid and B12 supplementation at levels higher than the general adult RDA (PubMed; confirm the specific dose ranges cited against current ASMBS guidance before publishing exact numbers). Adding metformin in this group is a reason for closer B12 monitoring, not a reason to change the folate protocol itself.

Patients on Proton Pump Inhibitors

Proton pump inhibitors (PPIs) reduce gastric acid and can impair B12 absorption through a mechanism distinct from metformin's. Long-term PPI use has been associated with increased risk of B12 deficiency in large observational studies (PubMed; exact cohort size and risk increase should be verified before citing precisely). Combined PPI and metformin use creates two independent reasons for reduced B12 absorption, which is worth flagging to a clinician managing both medications.

Practical Guidance for People Already Taking Both

Most people already taking folate and metformin together are doing so without any problem. The points below address the questions that come up most often, and none of them replace a conversation with a treating clinician or pharmacist.

Confirm B12 status periodically, especially after several years of metformin use or at higher doses. Metformin dose and duration are consistently identified as risk factors for B12 deficiency in the literature (PubMed; specific dose and duration thresholds from this study should be verified before being presented as exact cutoffs).

If MTHFR C677T homozygosity or unexplained elevated homocysteine is confirmed, ask a clinician whether switching from folic acid to 5-MTHF (methylfolate) makes sense, rather than making the switch independently.

If homocysteine is being tracked, recheck it after B12 or folate adjustments rather than assuming a single baseline value tells the full story. Target homocysteine levels differ by clinical context and should be set by the treating clinician rather than a fixed number applied to everyone.

Do not stop metformin to protect B12 status. Metformin has long-established cardiovascular and glycemic benefits, most notably from the UKPDS 34 trial, which found reduced all-cause and diabetes-related mortality with metformin in overweight patients with type 2 diabetes (PubMed). B12 supplementation addresses the nutrient gap without requiring metformin discontinuation.